Comparison of insulin regimens for patients with type 2

Current Opinion in Endocrinology and Diabetes

Volumn 7, Issue 4, 2000, Pages 175-183

  Yki Järvinen, Hannele ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Division of Diabetes   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA DERIVATIVE;

DRUG ABSORPTION; DRUG HYPERSENSITIVITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0033925345     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200008000-00001     Document Type: Review

References (63)

1. 1 United Kingdom Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-852.
2. 2 Yki-Järvinen H, Kauppila M, Kujansuu E, et al.: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:1426-1433.
3. 3 Yki-Järvinen H, Ryysy L, Nikkila K, et al.: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999, 130:389-396. First study to compare various bedtime insulin regimens, especially use of bedtime NPH with metformin with other regimens. Showed clear benefits from use of metformin: better glycemic control, less weight gain and hypoglycemias.
4. 4 United Kingdom Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
5. 5 Malmberg K, Ryden L, Efendic S, et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57-65.
6. 6 Malmberg K: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997, 314:1512-1515.
7. 7 Ryysy L, Häkkinen A-M, Goto T, et al.: Liver fat content, insulin absorption and action as determinants of insulin requirements in type 2 diabetes. Diabetes 2000, 48:749-758. An extensive metabolic study searching for predictors of insulin requirements studing bedtime-insulin-metformin combination therapy. Insulin resistance, especially in the liver, was found to be the most important determinant of the daily insulin dose.
8. 8 Peters AL, Davidson MB: Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991, 115:45-53.
9. 9 Pugh JA, Wagner ML, Sawyer J, et al.: Is combination sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992, 15:953-959.
10. 10 Mäkimattila S, Nikkilä K, Yki-Järvinen H: Causes of weight gain during insulin therapy with and without metformin in patients with non-insulin-dependent diabetes mellitus. Diabetologia 1999, 42:406-412. Study showing that patients using metformin with insulin eat less that those who use insulin alone and that this effect explains why metformin counteracts weight gain during insulin therapy.
11. 11 Taskinen M-R, Kuusi T, Helve E, et al.: Insulin therapy induces antiathrogenic changes in serum lipoproteins in non-insulin-dependent diabetes mellitus. Arteriosclerosis 1988, 8:168-177.
12. 12 Gerich JE: Oral hypoglycemic agents. N Engl J Med 1989, 321:1231-1245.
13. 13 Riddle MC, Hart JS, Bouma DJ, et al.: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 1989, 12:623-629.
14. 14 Riddle MC, Schneider J: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998, 21:1052-1057.
15. 15 Riddle M, Hart J, Bingham P, et al.: Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 1992, 303:151-156.
16. 16 Chow C-C, Tsang LWW, Sorensen JP, et al.: Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995, 18:307-314.
17. 17 Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, el al.: Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996, 19:1326-1332.
18. 18 Relimpio F, Pumar A, Losada F, et al.: Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial. Diabetes Med 1998, 15:997-1002.
19. 19 Lindstrom T, Nystrom FH, Olsson AG, et al.: The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. Diabetes Med 1999, 16:820-826.
20. 20 Clauson PG, Linde B: Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 1995, 18:986-991.
21. 21 Aviles-Santa L, Sinding J, Raskin P: Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:182-188. This study showed that addition of metformin to the treatment regimen of patients who were previously on insulin alone markedly improved glycemic control without increasing hypoglycemias or body weight.
22. 22 Raskin P, Dole JF, Rappaport EB: Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated type 2 diabetes. Diabetes 1999, 48:A94(abstract).
23. 23 Schwartz S, Raskin P, Fonseca V, et al.: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group [see comments]. N Engl J Med 1998, 338:861-866.
24. 24 Rubin C, Egan J, Schneider R, et al.: Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes 1999, 48:A110(abstract).
25. 25 Landstedt-Hallin L, Adamson U, Arner P, et al.: Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995, 18:1183-1186.
26. 26 Bastyr EJ, Johnson ME, Trautmann ME, et al.: Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999, 21:1703-1714.
27. 27 Bolli GB, Di Marchi RD, Park GD, et al.: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999, 42:1151-1167.
28. 28 Rosenstock J, Schwartz S, Clark C, et al.: Efficacy and safety of HOE901 (Insulin Glargine) in subjects with type 2 DM: A 28-week randomized, NPH insulin-controlled trial. Diabetes 1999, 48:A100(abstract).
29. 29 Vignati L, Anderson JHJ, Iversen PW: Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 1997, 19:1408-1421.
30. 30 Pinies JA, Ugarte E, Alonso J, et al.: Comparation of intensive therapy with mixed lispro/NPH versus regular/NPH insulin in type 2 dm. Diabetologia 1998, 41(suppl1):A244(abstract).
31. 31 Boss AH, Raskin P, McGill J, et al.: Human insulin analog (insulin aspart, IAsp) is comparable to human insulin (HI) in type 2 diabetes. Diabetes 1999, 48(suppl1):A355(abstract).
32. 32 Knowler WC, Pettitt DJ, Savage RJ, et al.: Diabetes incidence in Pima Indians: contributions of obesity and parental diabetes. Am J Epidemiol 1981, 113:144-156.
33. 33 Bogardus C, Taskinen M-R, Zawadzki J, et al.: Increased resting metablic rates in obese subjects with non-insulin-dependent diabetes mellitus and the effect of sulfonylurea therapy. Diabetes 1986, 35:1-5.
34. 34 Welle S, Nair KS, Lockwood D: Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus. J Clin Endocrinol Metab 1988, 66:593-597.
35. 35 Franssila-Kallunki A, Groop L: Factors associated with basal metabolic rate in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992, 35:962-966.
36. 36 Turner R, Stratton I, Horton V, et al.: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group [published erratum appears in Lancet 1998 351 (9099):376]. Lancet 1997, 350:1288-1293.
37. 37 Landstedt-Hallin L, Arner P, Lins PE, et al.: The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team. Diabet Med 1999, 16:827-834.
38. 38 Muller UA, Muller R, Starrach A, et al.: Should insulin therapy in type 2 diabetic patients be started on an out-or inpatient basis? Results of a prospective controlled trial using the same treatment and teaching programme in ambulatory care and a university hospital. Diabetes Metab 1998, 24:251-255.
39. 39 Quatraro A, Consoli G, Ceriello A, et al.: Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabetes Metab 1986, 12:315-318.
40. 40 Bachmann W, Lotz N, Mehnert H, et al.: Effectiveness of combined treatment with glibenclamide and insulin in secondary sulfonylurea failure. A controlled multicenter double-blind clinical trial]. Dtsch Med Wochenschr 1988, 113:631-636.
41. 41 Robinson AC, Burke J, Robinson S, et al.: The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control [see comments]. Diabetes Care 1998, 21:701-705.
42. 42 Giugliano D, Quatraro A, Consoli G, et al: Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993, 44:107-112.
43. 43 Lins PE, Lundblad S, Persson-Trotzig E, et al.: Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Acta Med Scand 1988, 223:171-179.
44. 44 Stenman S, Groop P-H, Saloranta C, et al.: Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 1988, 31:206-213.
45. 45 Kitabchi AE, Soria AG, Radparvar A, et al.:Combined therapy of insulin and tolazamide decreases insulin requirement and serum triglycerides in obese patients with noninsulin-dependent diabetes mellitus. Am J Med Sci 1987, 294:10-14.
46. 46 Reich A, Abraira C, Lawrence AM: Combined glyburide and insulin therapy in type II diabetes. Diabetes Res 1987, 6:99-104.
47. 47 Lewitt MS, Yu VK, Rennie GC, et al.: Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care 1989, 12:379-383.
48. 48 Osei K, O'Dorisio TM, Falko JM: Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism. Am J Med 1984, 77:1002-1009.
49. 49 Schade DS, Mitchell WJ, Griego G: Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. JAMA 1987, 257:2441-2445.
50. 50 Gutniak M, Karlander S-G, Efendic S: Glyburide decreases insulin requirement, increases β-cell response to mixed meal, and does not affect insulin sensitivity: Effects of short-and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 1987, 10:545-554.
51. 51 Kyllastinen M, Groop L: Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Ann Clin Res 1985, 17:100-104.
52. 52 Groop L, Harno K, Nikkila EA, et al.: Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. Acta Med Scand 1985, 217:33-39.
53. 53 Feinglos MN, Thacker CR, Lobaugh B, et al.: Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. Diabetes Res Clin Pract 1998, 39:193-199.
54. 54 Groop L, Harno K, Tolppanen EM: The combination of insulin and sulphonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta Endocrinol (Copenh) 1984, 106:97-101.
55. 55 Longnecker MP, Elsenhans VD, Leiman SM, et al.: Insulin and a sulfonylurea agent in non-insulin-dependent diabetes mellitus. Arch Intern Med 1986, 146:673-676.
56. 56 Casner PR: Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial. Clin Pharmacol Ther 1988, 44:594-603.
57. 57 Kelley DE, Bidot P, Freedman Z, et al.: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998, 21:2056-2061.
58. 58 Chiasson J-L, Josse RG, Hunt JA, et al.: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multi-center controlled clinical trial. Ann Intern Med 1994, 121:928-935.
59. 59 Weiss SR, Berger S, Cheng S-L, et al.: Adjunctive therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: A multicenter phase II trial. Diabetes 1999, 48:A12(Abstract)
60. 60 Groop LC, Widen E, Ekstrand A, et al.: Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM. Diabetes Care 1992, 15:831-834.
61. 61 Soneru IL, Agrawal L, Murphy JC, et al.: Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care 1993, 16:896-901.
62. 62 Malmberg K, Ryden L, Efendic S, et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 1998, 26:57-65.
63. 63 Bastyr EJ III, Johnson ME, Trautmann ME, et al.: Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999, 21:1703-1714.